- Home
- TRDA
as 04-18-2025 1:44pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 502.9M | IPO Year: | 2021 |
| Target Price: | $25.67 | AVG Volume (30 days): | 168.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.10 - $21.79 | Next Earning Date: | 05-06-2025 |
| Revenue: | $210,782,000 | Revenue Growth: | 63.38% |
| Revenue Growth (this year): | -82.25% | Revenue Growth (next year): | -23.10% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Mar 17 '25 | Sell | $10.67 | 1,784 | $19,035.28 | 109,536 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Clinical Trials Arena
25 days ago
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment
MT Newswires
a month ago
Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK
GlobeNewswire
a month ago
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Simply Wall St.
2 months ago
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next
Zacks
2 months ago
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
GlobeNewswire
2 months ago
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Zacks
2 months ago
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.